Kaletra Tablets(Lopinavir/Ritonavir)
KALETRA Rx Generic Name and Formulations:
Lopinavir, ritonavir; 100mg/25mg, 200mg/50mg; tabs.

Company:
AbbVie
Indications for KALETRA:
HIV-1 infection.

Adult:
Swallow tabs whole; take oral soln with food. Lopinavir/ritonavir 400/100mg (two 200/50mg tabs or 5mL) twice daily or 800/200mg (four 200/50mg tabs or 10mL) once daily (in patients with less than 3 lopinavir resistance-associated substitutions). Once-daily administration not recommended if ≥3 lopinavir resistance-associated substitutions or if given in combination with carbamazepine, phenobarbital, phenytoin, or if pregnant (also: avoid oral soln). Concomitant efavirenz, nevirapine, or nelfinavir: 500/125mg (two 200/50mg tabs and one 100/25mg tab) or 520/130mg (6.5mL) twice daily.

Children:
May use tabs if able to swallow whole and ≥15kg. Take oral soln with food. Postnatal age <14days or postmenstrual age of <42weeks: not recommended. 14days–6months: lopinavir/ritonavir 16/4mg/kg or 300/75mg/m2 twice daily. Do not administer with efavirenz, nevirapine, or nelfinavir. ≥6months: lopinavir/ritonavir 230/57.5mg/m2 twice daily or <15kg: 12/3mg/kg twice daily; ≥15–40kg: 10/2.5mg/kg twice daily; >40kg: max 400/100mg twice daily. Concomitant efavirenz, nevirapine, or nelfinavir: ≥6months: 300/75mg/m2 twice daily or <15kg: 13/3.25mg/kg twice daily; ≥15–45kg: 11/2.75mg/kg twice daily; >45kg: max oral soln: 520/130mg (6.5mL) twice daily; or max tabs: 500/125mg twice daily. See full labeling.

Contraindications:
Drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions. Potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance (eg, alfuzosin, rifampin, St. John's wort, lovastatin, simvastatin, sildenafil [Revatio], cisapride, ergots, pimozide, orally administered midazolam, triazolam).

Warnings/Precautions:
Suspend if pancreatitis occurs. History of, or risk factors for, pancreatitis (eg, elevated triglycerides). Hepatic impairment. Hepatitis. Diabetes. Monitor: lipids at baseline then periodically, ALT/AST in liver disease, for hyperglycemia or fat redistribution, hemophiliacs (for spontaneous bleed). Underlying structural heart disease. Pre-existing conduction system abnormalities. Ischemic heart disease. Cardiomyopathies. Elderly. Pregnancy. Nursing mothers: not recommended.

Interactions:
See Contraindications. Salmeterol, boceprevir, simeprevir: not recommended. Avoid oral soln with metronidazole, disulfiram. Potentiates statins metabolized by CYP3A; use atorvastatin with caution and at the lowest necessary doses; do not exceed rosuvastatin 10mg daily. Potentiates sildenafil, vardenafil, tadalafil (reduce dose of these); avanafil, fluticasone (avoid). Potentiates fentanyl, parenteral midazolam; monitor. Potentiates anticancer agents (eg, vincristine, vinblastine, dasatinib, nilotinib); may need dose adjustment (see full labeling). Concomitant colchicine (see full labeling); avoid in renal or hepatic impairment. Potentiates bosentan (see full labeling). Increases levels of antiarrhythmics, dihydropyridine CCBs, immunosuppressants (monitor); ketoconazole, itraconazole (avoid high doses); bedaquiline (use only if benefit outweighs the risk); rifabutin (reduce rifabutin dose and monitor); clarithromycin (reduce clarithromycin dose in renal dysfunction), trazodone (reduce trazodone dose), maraviroc (give max maraviroc 150mg twice daily), quetiapine (reduce dose), rilpivirine. Monitor other antiretrovirals, warfarin. Avoid concomitant rivaroxaban; increased bleeding risk. Decrease levels of atovaquone, methadone, bupropion, etravirine, estrogen-containing oral contraceptives (use other or back-up contraception), voriconazole (avoid and use alternatives). Lopinavir levels decreased by anticonvulsants (eg, carbamazepine, phenobarbital, phenytoin), budesonide, dexamethasone, prednisone, efavirenz, nevirapine. Lopinavir levels may be increased by delavirdine, CYP3A inhibitors. May decrease lamotrigine, valproate, zidovudine or abacavir levels. Give didanosine 1 hour before or 2 hours after. See full labeling.

See Also:
KALETRA ORAL SOLUTION

Pharmacological Class:
Protease inhibitor.

Adverse Reactions:
Diarrhea, nausea, vomiting, hypertriglyceridemia, hypercholesterolemia, asthenia, headache, abdominal pain, rash, insomnia, pancreatitis, fat redistribution, PR & QT prolongation, immune reconstitution syndrome.

How Supplied:
100mg/25mg—60; 200mg/50mg—120; Soln—160mL (w. dose cup)